Codexis narrows Q2 loss, raises $25M to fund GMP expansion
Codexis Inc. narrowed its Q2 2026 net loss to $12.0 million on $14.9 million in revenue, beating EPS estimates. A $25 million equity raise extends cash runway to 2028, funding GMP expansion and siRNA platform development.
*this image is generated using AI for illustrative purposes only.
Codexis Inc. (NASDAQ: CDXS) reported a second-quarter 2026 net loss of $12.0 million, or $(0.13) per share, beating analyst estimates of $(0.14) while narrowing losses from the prior year’s $(13.3) million. The enzymatic solutions provider also completed an equity financing raising approximately $25 million in net proceeds in July, strengthening its balance sheet to approximately $80 million in proforma cash. This capital injection secures the company’s operations through the end of 2028, funding the critical retrofit of its ECO GMP Manufacturing Center intended for siRNA production.
The financial results reflect disciplined cost management alongside revenue pressures. Total revenues stood at $14.9 million for the quarter, a 2.69 percent decline from $15.3 million in Q2 2025, driven primarily by lower research and development revenue. However, this was partially offset by higher product revenue, fueled by the launch of new, higher-margin products by customers. Product gross margin improved to 73 percent from 72 percent in the prior-year period, indicating a favorable shift in sales mix toward more profitable offerings.
Financial Performance Overview
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Total Revenue ($M) | 14.9 | 15.3 | -2.69% |
| Net Loss ($M) | (12.0) | (13.3) | -9.77% |
| EPS ($) | (0.13) | (0.16) | +18.75% |
| Product Gross Margin | 73% | 72% | +100 bps |
Operating expenses decreased significantly, contributing to the narrowed loss. Research and development expenses fell to $11.7 million from $13.8 million, due to lower employee-related costs and reduced spending on outside services. Selling, general, and administrative expenses dropped to $10.9 million from $12.3 million, aided by reduced headcount and lower stock-based compensation. As of June 30, 2026, Codexis held $54.9 million in cash, cash equivalents, and short-term investments before the July equity raise.
Strategic Developments and Guidance
Beyond financial metrics, Codexis highlighted progress in its ECO Synthesis Manufacturing Platform. At the TIDES US annual meeting in May, the company presented data demonstrating enzyme-driven stereoisomer control of siRNA, potentially enhancing potency and product quality. This technological advancement has generated strong interest from both startups and established players in the siRNA field.
Looking ahead, Codexis reiterated its full-year 2026 guidance, projecting total revenues between $72 million and $76 million, with gross margins in the high 60 percent range. The company plans to submit a building permit application for its ECO GMP Manufacturing Center in the second half of 2026, with full production capability targeted by the end of 2027. The facility will supply siRNA material for preclinical investigations and Phase 1 clinical trials. Additionally, Codexis aims to expand relationships with contract development and manufacturing organization (CDMO) partners and advance partnerships with drug innovators toward clinical-stage manufacturing agreements.
What the Numbers Show
The divergence between declining top-line revenue and improving profitability metrics suggests Codexis is successfully optimizing its cost structure even as it navigates a transitional phase in its revenue streams. The reduction in R&D and SG&A expenses, combined with an improving gross margin profile, indicates operational efficiency gains. However, the reliance on new product launches to offset declines in established R&D revenue highlights the importance of customer adoption cycles. The recent $25 million capital raise mitigates near-term liquidity risks, providing ample runway to execute on its GMP facility expansion without immediate pressure for additional dilutive financing.
How might the successful retrofit of the ECO GMP Manufacturing Center impact Codexis's competitive positioning against other CDMOs specializing in siRNA production?
What specific milestones or regulatory approvals are required for Codexis to convert its current interest from siRNA innovators into binding clinical-stage manufacturing agreements?
Could the continued decline in R&D revenue signal a broader industry shift away from early-stage enzymatic discovery services, and how is Codexis adapting its business model to mitigate this risk?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
